263 related articles for article (PubMed ID: 37950758)
21. Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer's Disease Continuum.
Lehmann S; Schraen-Maschke S; Vidal JS; Blanc F; Paquet C; Allinquant B; Bombois S; Gabelle A; Delaby C; Hanon O;
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139190
[TBL] [Abstract][Full Text] [Related]
22. Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia.
Ingannato A; Bagnoli S; Mazzeo S; Giacomucci G; Bessi V; Ferrari C; Sorbi S; Nacmias B
Front Endocrinol (Lausanne); 2024; 15():1375302. PubMed ID: 38654932
[TBL] [Abstract][Full Text] [Related]
23. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
Benedet AL; Milà-Alomà M; Vrillon A; Ashton NJ; Pascoal TA; Lussier F; Karikari TK; Hourregue C; Cognat E; Dumurgier J; Stevenson J; Rahmouni N; Pallen V; Poltronetti NM; Salvadó G; Shekari M; Operto G; Gispert JD; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Zimmer ER; Zetterberg H; Molinuevo JL; Paquet C; Rosa-Neto P; Blennow K; Suárez-Calvet M;
JAMA Neurol; 2021 Dec; 78(12):1471-1483. PubMed ID: 34661615
[TBL] [Abstract][Full Text] [Related]
24. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.
Giannisis A; Al-Grety A; Carlsson H; Patra K; Twohig D; Sando SB; Lauridsen C; Berge G; Grøntvedt GR; Bråthen G; White LR; Kultima K; Nielsen HM
Alzheimers Res Ther; 2022 Aug; 14(1):115. PubMed ID: 36002891
[TBL] [Abstract][Full Text] [Related]
25. A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias.
Bolsewig K; Hok-A-Hin YS; Sepe FN; Boonkamp L; Jacobs D; Bellomo G; Paoletti FP; Vanmechelen E; Teunissen CE; Parnetti L; Willemse EAJ
J Alzheimers Dis; 2022; 90(1):363-380. PubMed ID: 36120776
[TBL] [Abstract][Full Text] [Related]
26. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.
Baiardi S; Quadalti C; Mammana A; Dellavalle S; Zenesini C; Sambati L; Pantieri R; Polischi B; Romano L; Suffritti M; Bentivenga GM; Randi V; Stanzani-Maserati M; Capellari S; Parchi P
Alzheimers Res Ther; 2022 Oct; 14(1):153. PubMed ID: 36221099
[TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer's disease.
Barba L; Abu Rumeileh S; Bellomo G; Paolini Paoletti F; Halbgebauer S; Oeckl P; Steinacker P; Massa F; Gaetani L; Parnetti L; Otto M
J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):83-86. PubMed ID: 35944974
[TBL] [Abstract][Full Text] [Related]
29. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias.
Abu-Rumeileh S; Capellari S; Stanzani-Maserati M; Polischi B; Martinelli P; Caroppo P; Ladogana A; Parchi P
Alzheimers Res Ther; 2018 Jan; 10(1):3. PubMed ID: 29368621
[TBL] [Abstract][Full Text] [Related]
30. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes.
Sjögren M; Blomberg M; Jonsson M; Wahlund LO; Edman A; Lind K; Rosengren L; Blennow K; Wallin A
J Neurosci Res; 2001 Nov; 66(3):510-6. PubMed ID: 11746370
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease.
Lista S; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Dos Santos AM; Epelbaum S; Lamari F; Dubois B; Floris R; Garaci F; Hampel H;
Neurochem Int; 2017 Sep; 108():355-360. PubMed ID: 28527630
[TBL] [Abstract][Full Text] [Related]
32. CSF neurofilament proteins in the differential diagnosis of dementia.
de Jong D; Jansen RW; Pijnenburg YA; van Geel WJ; Borm GF; Kremer HP; Verbeek MM
J Neurol Neurosurg Psychiatry; 2007 Sep; 78(9):936-8. PubMed ID: 17314187
[TBL] [Abstract][Full Text] [Related]
33. Future perspective and clinical applicability of the combined use of plasma phosphorylated tau 181 and neurofilament light chain in Subjective Cognitive Decline and Mild Cognitive Impairment.
Giacomucci G; Mazzeo S; Ingannato A; Crucitti C; Bagnoli S; Padiglioni S; Romano L; Galdo G; Emiliani F; Frigerio D; Ferrari C; Moschini V; Morinelli C; Notarelli A; Sorbi S; Nacmias B; Bessi V
Sci Rep; 2024 May; 14(1):11307. PubMed ID: 38760423
[TBL] [Abstract][Full Text] [Related]
34. Blood biomarkers in mild cognitive impairment patients: Relationship between analytes and progression to Alzheimer disease dementia.
Silva-Spínola A; Lima M; Leitão MJ; Bernardes C; Durães J; Duro D; Tábuas-Pereira M; Santana I; Baldeiras I
Eur J Neurol; 2023 Jun; 30(6):1565-1573. PubMed ID: 36880887
[TBL] [Abstract][Full Text] [Related]
35. Neurofilament markers in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Shi J; Qin X; Chang X; Wang H; Guo J; Zhang W
J Cell Mol Med; 2022 Jan; 26(2):583-587. PubMed ID: 34866307
[TBL] [Abstract][Full Text] [Related]
36. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
[TBL] [Abstract][Full Text] [Related]
37. CSF neurofilament light may predict progression from amnestic mild cognitive impairment to Alzheimer's disease dementia.
Lim B; Grøntvedt GR; Bathala P; Kale SS; Campbell CT; Stengelin M; Sando SB; Prassas I; Diamandis EP; Bråthen G
Neurobiol Aging; 2021 Nov; 107():78-85. PubMed ID: 34403936
[TBL] [Abstract][Full Text] [Related]
38. Neurofilament levels in patients with neurological diseases: A comparison of neurofilament light and heavy chain levels.
Kušnierová P; Zeman D; Hradílek P; Čábal M; Zapletalová O
J Clin Lab Anal; 2019 Sep; 33(7):e22948. PubMed ID: 31199010
[TBL] [Abstract][Full Text] [Related]
39. Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population.
Gleerup HS; Sanna F; Høgh P; Simrén J; Blennow K; Zetterberg H; Hasselbalch SG; Ashton NJ; Simonsen AH
Front Aging Neurosci; 2021; 13():659898. PubMed ID: 34040512
[TBL] [Abstract][Full Text] [Related]
40. Comparison of different MRI-based morphometric estimates for defining neurodegeneration across the Alzheimer's disease continuum.
Allison SL; Koscik RL; Cary RP; Jonaitis EM; Rowley HA; Chin NA; Zetterberg H; Blennow K; Carlsson CM; Asthana S; Bendlin BB; Johnson SC
Neuroimage Clin; 2019; 23():101895. PubMed ID: 31252287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]